Loading...

Paion AG

0NF3.L•LSE
Healthcare
Medical - Pharmaceuticals
£0.01
£-0.00(-25.33%)

Paion AG (0NF3.L) Stock Overview

Explore Paion AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.6/100

Key Financials

Market Cap79.9K
P/E Ratio-4.44
EPS (TTM)$-0.31
ROE-0.09%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.22

0NF3.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Paion AG (0NF3.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 0.00, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.22.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.44 and a market capitalization of 79.9K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

0.00RSI (14)
0.00MACD
0.00ADX
Stats data is not available for 0NF3.LStats details for 0NF3.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0NF3.LAnalyst Recommendations details for 0NF3.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

CEO

Gregor Siebert

Employees

64

Headquarters

Heussstrasse 25, Aachen

Founded

2023

Frequently Asked Questions

;